Athersys Fails Stroke Trial In Mid-Stage Study By: TalkMarkets April 17, 2015 at 13:02 PM EDT Shares of Athersys are down almost 50% on the news of failing a phase 2 trial for stroke with the company using its multistem cell therapy Read More >> Related Stocks: Athersys Inc Pfizer